Established in 2016 with successful angel round financing.

Launched GMP cell laboratory in 2017.

Achieved the first super donor hiPSC from the Chinese population in 2018.
Also in 2018, we took on special project "Standardization Research on Stem Cell Preparations and Applications" under the National Key Research and Development Program of the Ministry of Science and Technology of the People's Republic of China.

In 2019, we accelerated the research and development of cell drugs.

In 2020, we are on track to establish a super donor hiPSC bank tailored for the Chinese population, covering over 50% of the nation.

We proudly accepted the responsibility of leading the special project "Quality Control and Evaluation Technology of Stem Cells and Related Products" under the National Key Research and Development Program of the Ministry of Science and Technology of the People's Republic of China in 2021.

In 2022, a significant milestone was achieved as China's first iPSC-iMSC received IND approval,
coupled with the successful completion of a Series A financing round raising hundreds of millions of yuan.

In 2023, we reached another groundbreaking achievement with the IND approval of China's first iPSC-iNK, marking a pivotal moment as we continue to advance and innovate in the field.
Stay tuned for further updates on our progress.